| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 2 | HKEx | ||
| 05.11. | EXTRAWELL PHAR (00858): PLACING OF NEW SHARES UNDER GENERAL MANDATE SUPPLEMENTAL ANNOUNCEMENT | - | HKEx | ||
| 05.11. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | 2 | HKEx | ||
| 05.11. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 05.11. | EXTRAWELL PHAR (00858): NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 05.11. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON MONDAY, 30 NOVEMBER 2026 AT 10:00 A.M. | - | HKEx | ||
| 05.11. | EXTRAWELL PHAR (00858): PROPOSED SHARE CONSOLIDATION; PROPOSED CAPITAL REDUCTION; PROPOSED SHARE SUB-DIVISION; PROPOSED CHANGE IN BOARD LOT SIZE AND NOTICE ... | - | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 30.10. | EXTRAWELL PHAR (00858): FURTHER DELAY IN DESPATCH OF THE CIRCULAR AND FURTHER EXTENSION OF THE LONG STOP DATE IN RELATION TO THE MAJOR TRANSACTION INVOLVING ... | - | HKEx | ||
| 30.10. | EXTRAWELL PHAR (00858): PLACING OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 21.10. | EXTRAWELL PHAR (00858): GRANT OF SHARE OPTIONS TO DIRECTORS AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO THE GRANT OF SHARE OPTIONS TO ... | 1 | HKEx | ||
| 16.10. | EXTRAWELL PHAR (00858): TERMINATION OF THE MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS | 3 | HKEx | ||
| 14.10. | EXTRAWELL PHAR (00858): PROPOSED SHARE CONSOLIDATION; PROPOSED CAPITAL REDUCTION; PROPOSED SHARE SUB-DIVISION AND PROPOSED CHANGE IN BOARD LOT SIZE | - | HKEx | ||
| 12.10. | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 12.10. | EXTRAWELL PHAR (00858): APPOINTMENT OF EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 30.09. | EXTRAWELL PHAR (00858): FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS | 3 | HKEx | ||
| 11.09. | EXTRAWELL PHAR (00858): FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE ... | 1 | HKEx | ||
| 28.08. | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 28.08. | EXTRAWELL PHAR (00858): POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 AUGUST 2026 AND RETIREMENT OF DIRECTOR | - | HKEx | ||
| 30.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2026, CIRCULAR DATED 31 ... | 4 | HKEx | ||
| 30.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2026, CIRCULAR DATED 31 ... | 2 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 25,420 | +1,68 % | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) | - TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG =880 mg/dL (=10 mmol/L) - - Approximately 700,000 people in the EU5 are estimated to have triglyceride... ► Artikel lesen | |
| CSPC PHARMA | 0,901 | 0,00 % | CSPC Pharmaceutical Group Ltd. Announces Rise In Nine Months Bottom Line | ||
| SELLAS LIFE SCIENCES | 16,650 | +1,83 % | Aktie verdreifacht sich: Sellas Life Sciences: Neuer Krebsimpfstoff beflügelt | © Foto: adobe.stock.comDie Aktie von Sellas Life Sciences verzeichnet nach überzeugenden Studiendaten zu einem experimentellen Blutkrebs-Impfstoff einen historischen Kurssprung Enthaltene Werte: US81642T2096Den... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 364,20 | +0,41 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ACADIA PHARMACEUTICALS | 16,555 | +1,88 % | Oppenheimer senkt Kursziel für Acadia Pharmaceuticals wegen Pipeline-Aussichten | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 3,620 | +1,12 % | Opus Genetics, Inc.: Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 | OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement... ► Artikel lesen | |
| SAVARA | 4,353 | +0,90 % | H.C. Wainwright initiates Savara stock coverage with buy rating | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information | Conference Call Scheduled for Friday, November 13, 2026 at 11:30 AM ESTNorthvale, New Jersey--(Newsfile Corp. - November 12, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company")... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,580 | +4,88 % | Galectin Therapeutics GAAP EPS of -$0.04 beats by $0.01 | ||
| BIODEXA PHARMACEUTICALS | 1,350 | -7,53 % | XFRA NEW INSTRUMENTS AVAILABLE ON 28.10.2026 | The following instruments on XETRA do have their first trading 28.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.10.2026
Aktien
1 US59564R8640 Biodexa Pharmaceuticals... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,026 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: Bell Potter Healthcare Conference Presentation | ||
| CIPHER PHARMACEUTICALS | 8,250 | -1,20 % | CIPHER PHARMACEUTICALS INC Announces Advance In Q3 Profit | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| VASO | - | - | Vasomedical reports Q3 results |